Andrew X Zhu Selected Research

Erlotinib Hydrochloride (CP 358,774)

10/2016	Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
2/2015	SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
10/2007	Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
4/2006	Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew X Zhu Research Topics

Disease

132	Hepatocellular Carcinoma (Hepatoma) 02/2024 - 11/2004
117	Neoplasms (Cancer) 01/2023 - 06/2003
40	Cholangiocarcinoma 01/2024 - 01/2004
18	Liver Neoplasms (Liver Cancer) 10/2023 - 08/2007
17	Biliary Tract Neoplasms (Biliary Tract Cancer) 10/2021 - 02/2008
16	Fibrosis (Cirrhosis) 01/2023 - 01/2009
13	Adenocarcinoma 11/2021 - 01/2005
13	Pancreatic Neoplasms (Pancreatic Cancer) 07/2019 - 10/2004
12	Hypertension (High Blood Pressure) 02/2024 - 06/2004
12	Disease Progression 01/2024 - 01/2012
12	Liver Diseases (Liver Disease) 12/2022 - 12/2013
12	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 02/2004
10	Neoplasm Metastasis (Metastasis) 11/2018 - 01/2009
7	Fatigue 01/2021 - 04/2006
6	Ascites 11/2021 - 07/2015
6	Carcinoma (Carcinomatosis) 12/2020 - 02/2004
6	Diarrhea 12/2019 - 04/2006
6	Neuroendocrine Tumors (Neuroendocrine Tumor) 09/2013 - 06/2006
5	Rectal Neoplasms (Rectal Cancer) 01/2021 - 10/2003
5	Renal Cell Carcinoma (Grawitz Tumor) 01/2020 - 07/2006
5	Neutropenia 01/2010 - 04/2006
4	Asthenia 02/2024 - 07/2014
4	Hypoxia (Hypoxemia) 01/2022 - 11/2011
3	Hepatitis 02/2023 - 06/2003
3	Thrombosis (Thrombus) 05/2020 - 01/2012
3	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2020 - 01/2012
3	Vomiting 12/2019 - 04/2006
3	Nausea 12/2019 - 04/2006
3	Thrombocytopenia (Thrombopenia) 07/2015 - 11/2006
2	Multiple Organ Failure (MODS) 02/2024 - 01/2022
2	Varicose Veins (Varicose Vein) 02/2024 - 01/2022
2	Tumor Lysis Syndrome 02/2024 - 01/2022
2	Chemical and Drug Induced Liver Injury 02/2024 - 01/2022
2	Hepatic Encephalopathy 02/2024 - 01/2022
2	Inflammation (Inflammations) 01/2022 - 12/2020
2	Thrombotic Microangiopathies 05/2021 - 06/2004
2	Pain (Aches) 01/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

43	Sorafenib (BAY 43-9006)FDA Link 02/2024 - 01/2008
34	Biomarkers (Surrogate Marker)IBA 11/2022 - 11/2005
21	RamucirumabIBA 12/2022 - 12/2013
20	Bevacizumab (Avastin)FDA Link 10/2023 - 02/2004
17	Gemcitabine FDA Link 10/2021 - 06/2004
13	atezolizumabIBA 02/2024 - 01/2020
12	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2022 - 07/2009
12	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 02/2004
11	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 01/2024 - 01/2012
11	Oxaliplatin (Eloxatin)FDA LinkGeneric 07/2019 - 04/2006
10	Irinotecan (Camptosar)FDA LinkGeneric 07/2019 - 04/2006
9	RNA (Ribonucleic Acid)IBA 01/2022 - 12/2015
8	AlbuminsIBA 10/2023 - 10/2014
8	Protons (Proton)IBA 04/2020 - 07/2014
8	Fluorouracil (Carac)FDA LinkGeneric 07/2019 - 02/2004
8	ErbB Receptors (EGF Receptor)IBA 07/2016 - 05/2006
7	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2024 - 08/2007
7	pembrolizumabIBA 01/2022 - 01/2018
7	Tyrosine Kinase InhibitorsIBA 01/2021 - 05/2006
7	Proteins (Proteins, Gene)FDA Link 07/2016 - 11/2006
7	Everolimus FDA Link 01/2016 - 11/2011
7	Sunitinib (Sutent)FDA Link 08/2014 - 01/2009
6	Alanine Transaminase (SGPT)IBA 02/2024 - 01/2010
6	Fetal Proteins (Fetoprotein)IBA 12/2022 - 01/2012
6	Immune Checkpoint InhibitorsIBA 11/2022 - 11/2014
6	Leucovorin (Folinic Acid)FDA Link 07/2019 - 02/2004
6	Phosphotransferases (Kinase)IBA 01/2019 - 01/2009
5	ivosidenibIBA 01/2024 - 01/2019
5	Cytidine Triphosphate (CTP)IBA 01/2018 - 02/2008
4	BilirubinIBA 10/2023 - 07/2015
4	infigratinibIBA 10/2021 - 01/2017
4	Cisplatin (Platino)FDA LinkGeneric 12/2020 - 06/2006
4	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2020 - 07/2009
4	Capecitabine (Xeloda)FDA Link 07/2019 - 04/2006
4	folfirinoxIBA 07/2019 - 01/2013
4	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2016 - 04/2006
4	DNA (Deoxyribonucleic Acid)IBA 01/2016 - 12/2015
4	Cetuximab (Erbitux)FDA Link 01/2012 - 05/2006
3	cabozantinibIBA 02/2024 - 01/2017
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2022 - 01/2009
3	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 01/2021 - 07/2016
3	Monoclonal AntibodiesIBA 06/2019 - 01/2012
3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 01/2011
3	AntigensIBA 03/2014 - 01/2005
2	tislelizumabIBA 10/2023 - 06/2019
2	AntibodiesIBA 01/2023 - 01/2020
2	InterferonsIBA 01/2023 - 06/2003
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022 - 01/2017
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022 - 10/2016
2	Circulating Tumor DNAIBA 01/2021 - 01/2017
2	Indicators and Reagents (Reagents)IBA 01/2021 - 10/2014
2	lenvatinibIBA 12/2020 - 10/2020

Therapy/Procedure

96	Therapeutics 10/2023 - 06/2003
29	Drug Therapy (Chemotherapy) 12/2022 - 06/2003
22	Radiotherapy 11/2021 - 01/2005
10	Immunotherapy 01/2023 - 01/2005
7	Neoadjuvant Therapy 01/2021 - 06/2012
6	Liver Transplantation 01/2019 - 11/2004
6	Aftercare (After-Treatment) 01/2018 - 05/2006
5	Proton Therapy 01/2018 - 07/2014
4	Radiofrequency Ablation 04/2015 - 04/2008
3	Adjuvant Chemotherapy 01/2018 - 08/2010
3	Surgical Instruments (Clip) 12/2013 - 08/2007